Sofgen Pharma S.A
PROCF Healthcare Drug Manufacturers Specialty & Generic
Follow PROCF
Sofgen Pharma S.A (PROCF) Piotroski F-score
Sofgen Pharma S.A's Piotroski F-score for fiscal 2024 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2024 | 3 | — |
How fiscal 2024’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (15.45%) | 8.82% | Fail | 0 |
| Positive operating cash flow | 88.43m | 107.64m | Pass | 1 |
| Rising return on assets | (15.45%) | 8.82% | Fail | 0 |
| Cash flow above net income | 156.73m | 67.29m | Pass | 1 |
| Falling long-term leverage | 0.09 | 0.07 | Fail | 0 |
| Rising current ratio | 0.52 | 0.64 | Fail | 0 |
| No new shares issued | 100,271,000 | 101,006,000 | Pass | 1 |
| Rising gross margin | 51.23% | 56.16% | Fail | 0 |
| Rising asset turnover | 0.85 | 0.93 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| CPIX Cumberland Pharmaceuticals Inc. compare | 6 |
| OGI Organigram Global Inc. compare | 5 |
| ORGO Organogenesis compare | 4 |
| DERM Journey Medical Corporation compare | 4 |
| BGM BGM Group Ltd. compare | 3 |
| CLVR Clever Leaves Holdings Inc. compare | 3 |
| PROCF Sofgen Pharma S.A | 3 |
| CTOR Citius Oncology, Inc. compare | — |
| CRDL Cardiol Therapeutics Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover